Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer
A molecular risk score in treatment-naïve mCRPC state obtained either in metastatic tissue or cfDNA predicts clinical survival outcomes and offers a tumor biology-based tool to design biomarker-based enrichment clinical trials.
Authors
- Bogdana Schmidt (ORCID: https://orcid.org/0000-0002-1233-1638)
- Corinne Maurice‐Dror (ORCID: https://orcid.org/0000-0003-4455-4497)
- Aik Choon Tan (ORCID: https://orcid.org/0000-0003-2955-8369)
- Manish Kohli (ORCID: https://orcid.org/0000-0002-9735-6614)
- David A. Nix (ORCID: https://orcid.org/0009-0002-3383-8582)
- Alexander W. Wyatt (ORCID: https://orcid.org/0000-0003-2399-0329)
- Muhammad Zaki Hidayatullah Fadlullah (ORCID: https://orcid.org/0000-0002-3111-8090)
- Brayden Fairbourn
- Cameron Herberts
- Liang Wang (ORCID: https://orcid.org/0000-0002-9364-8572)
Institutions
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- University of Utah (US)
- Spencer Foundation (US)
- Huntsman Cancer Institute (US)
- Moffitt Cancer Center (US)
- Canada's Michael Smith Genome Sciences Centre (CA)
- The Prostate Centre (GB)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1093/jncics/pkaf025
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04